SK bioscience : Conclusion of Single SalesContract or Supply Contract

Report of Disclosure Revision

Revision Date

2022-07-20

1. Disclosure Documents in relation with Revision	Conclusion of Single Sales Contract or Supply Contract
2. Submission date of documents	2022-01-19
3. Reason for Revision	Change contract contents
4. Revised Information
information	before revision	after revision
9. Other matters to be factored into investment decision	- The above sales amount is the company's sales based on the last year's individual financial statements.	- The above sales amount is the company's sales based on the FY 2020 individual financial statements. - Under the contract amendment, SK bioscience will manufacture variant-targeting vaccine(DS) instead of the drug substance of original antigen that was previously contracted.

-

Conclusion of Single Sales Contract or Supply Contract

1. Type of sales or supply contract	Other sales or supply contracts
- Name of contract concluded	COVID-19 Vaccine CMO Contract
2. Details of contract	Contract amount (KRW)	131,627,600,000
Sales of the latest fiscal year (KRW)	225,610,784,857
Ratio to sales (%)	58.34
Classified as a large-sized corporation?	No
3. Counterparty to contract	Novavax, Inc.
- Relationship to company	-
4. Regions of sales or supply (markets served)	-
5. Contract period	Start date	2021-12-23
End date	2022-12-31
6. Terms and conditions of contract	Production and supply of Novavax's COVID-19 Vaccine(DS)
7. Effective date of contract (receipt of orders)	2021-12-23
8. Withholding of disclosure	Reasons for withholding disclosure	-
Withholding period	-
9. Other matters to be factored into investment decisions
- The above contract amount is the amount obtained by applying the initial basic exchange rate (KRW 1,191.20/USD) as of Dec 23, 2021 to USD 110,500,000, an increase of USD 15,600,000 at the client's request from the initially disclosed contract amount of USD 94,900,000. - The above sales amount is the company's sales based on the FY 2020 individual financial statements. - The above contract amount may change depending on the actual quantity of purchase. - The above contract period may differ depending on revisions of the contract terms by consensus. - Under the contract amendment, SK bioscience will manufacture variant-targeting vaccine(DS) instead of the drug substance of original antigen that was previously contracted.
※ Related disclosure	2021-12-24 Conclusion of Single Sales Contract or Supply Contract 2022-01-20 Conclusion of Single Sales Contract or Supply Contract